DocTIS’ research to be presented at Immunology 2025

The annual meeting of the American Association of Immunologists is recognised as the world’s largest all-immunology event. Its 108th edition, Immunology 2025, will take place from 3–7 May 2025, at the Hawaii Convention Center in Honolulu, Hawaii, USA. The meeting will feature over 800 speakers across more than 100 sessions and is expected to welcome more than 3,500 attendees from over 40 countries. Participants will also have the opportunity to explore up to 2,000 abstracts presented in both podium and poster sessions.

DocTIS will take a prominent role at the conference with an oral presentation by Antonio Julià, head of the Rheumatology Research Group from the project’s coordinating institution, VHIR. He will present the research entitled “Uncovering combination therapies for Immune-Mediated Inflammatory Diseases through systems biology analysis on longitudinal patient data” on Monday, 5 May at 16:15 in Room 312 of the Hawaii Convention Center, as part of the “Block Symposia” sessions.

This work, developed by all of DocTIS’ scientific partners (VHIR, CNAG, IDIBAPS, Cardiff University, Charité, the University of Verona, HudsonAlpha and IMIDomics Inc,), leverages systems biology and longitudinal molecular patient data across multiple immune-mediated inflammatory diseases (IMIDs) to identify synergistic drug combinations. Using bulk and single-cell transcriptomics the DoCTIS partners have developed a new methodology that provides strong support for new therapeutic combinations that could overcome treatment resistance in diseases like rheumatoid arthritis.

Visit immunology2025.aai.org for more information about this event, and make sure you don’t miss Antonio Julià’s presentation!

About the DocTIS Project

The DocTIS project is an EU-funded initiative aiming to improve the treatment of six immune-mediated inflammatory diseases (IMIDs):

• Ulcerative colitis
• Crohn’s disease
• Psoriasis
• Psoriatic arthritis
• Rheumatoid arthritis
• Systemic lupus erythematosus

By leveraging advanced technologies and systems biology, DocTIS seeks to identify combination therapies that are safer and more effective than current single-drug treatments. The ultimate goal is to deliver more personalised and impactful care for individuals living with these chronic conditions.